Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine, Inc. (NASDAQ:IRON) with a price target of $85.00. The analyst based the rating on the company's positive developments in its hematology-focused pipeline.
A scientist in a laboratory setting examining a sample of blood with a microscope.
Smith stated that Disc Medicine, Inc. (NASDAQ:IRON) is set to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, that is anticipated to leverage an accelerated approval pathway. The HELIOS long-term extension study reported positive initial data supporting this progress, as it suggested improvements in live function, sustained reductions in PPIX, and a clean safety profile.
Disc Medicine, Inc. (NASDAQ:IRON) is also participating in ongoing trials, such as the Phase 2 RALLY-MF trial and the Phase 1b MF anemia trial, which have shown positive results with improved biomarker responses. The analyst considers this another positive factor supporting the buy rating.
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes treatments for hematologic diseases.
While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Errore nel recupero dei dati
Effettua l'accesso per consultare il tuo portafoglio
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pony AI (PONY) Soars 11.98% on Uber Acquisition
Pony AI Inc. (NASDAQ:PONY) is one of the . Pony AI grew its share prices by 11.98 percent on Thursday to finish at $14.58 apiece following news that Uber Technologies Inc.'s (NYSE:UBER) co-founder, Travis Kalanick, is setting his sights on the Chinese robotaxi firm's US subsidiary. Pony AI Inc. (NASDAQ:PONY), which went public only last year, has been mulling over selling or spinning off its US subsidiary since 2022, even going as far as creating a copy of its software. Reports added that Uber Technologies Inc. (NYSE:UBER) is ready to back Kalanick's acquisition plan. Acquiring Pony AI Inc. (NASDAQ:PONY) would bring Kalanick back to the transportation business since he was pushed out of his own co-founded company in 2017. A worker assembling parts in an automotive factory for an autonomous vehicle. The buyout bid followed Pony AI Inc. (NASDAQ:PONY) and Uber Technologies Inc.'s (NYSE:UBER) partnership of expanding the former's international market presence, kicking off with key markets in the Middle East. While we acknowledge the potential of PONY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Core Scientific (CORZ) Surges 33% as CoreWeave Revives Acquisition Bid
Core Scientific, Inc. (NASDAQ:CORZ) is one of the . Core Scientific rallied for a third straight day on Thursday, jumping 33.01 percent to close at $16.36 apiece following the revival of CoreWeave Inc.'s (NASDAQ:CRWV) bid to acquire the company. According to a report by the Wall Street Journal, citing people privy to the matter, CoreWeave Inc. (NASDAQ:CRWV) revived talks to acquire Core Scientific, Inc. (NASDAQ:CORZ) after its first attempt in 2024 fell through due to pricing issues. Both companies have yet to confirm or deny the reports ,but the Journal said that a deal is expected to be finalized in the coming weeks. An aerial view of an intricate network of digital infrastructure, lit up against a night sky. CoreWeave Inc. (NASDAQ:CRWV) has been instrumental to Core Scientific, Inc.'s (NASDAQ:CORZ) growth trajectory, having exited from bankruptcy through pivoting aggressively into Artificial Intelligence infrastructure in January last year. At present, the company is worth $5 billion in market capitalization. While we acknowledge the potential of CORZ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Should You Buy Rocket Lab While It's Below $40?
Rocket Lab stock is soaring on optimism over the rocket launch provider. The company is planning to unveil its next-generation rocket called the Neutron later this year. Rocket Lab stock looks overvalued at today's price levels. These 10 stocks could mint the next wave of millionaires › Space and defense stocks have gone to the moon this market cycle (pun intended). Rocket Lab (NASDAQ: RKLB) is one of the great beneficiaries of this trend, as the rocket launch, space systems, and defense company has seen its stock soar close to 600% in the last 12 months, absolutely crushing the broad market indices. It recently surpassed a price of $33, hitting a new all-time high in recent weeks. Investors are optimistic about the future of this space flight disrupter as it aims to compete with SpaceX. Should you buy the stock while it is still below $40? Or is it too late to add Rocket Lab to your portfolio? The answer may surprise you. Rocket Lab is the only independent space provider to come anywhere close to competing with SpaceX, the dominant player in the sector. It began its journey developing the small and nimble Electron rocket, which ferries commercial and defense payloads into space with extreme accuracy. Earlier this month, the 65th Electron rocket was launched into space, with many more waiting in Rocket Lab's backlog. The next step for Rocket Lab is the debut of its larger Neutron rocket, which will directly compete with SpaceX in size and capabilities. The Neutron will have a much higher payload capability than the Electron, which means more potential revenue per rocket launch. A Falcon 9 launch at SpaceX can cost over $50 million, which should be a comparable figure for the Neutron once it starts performing for customers. Management believes the Neutron will debut its first launch in 2025, with commercial launches planned in the years after. Rocket Lab's total revenue was only $466 million over the last 12 months, meaning that just a few annual Neutron launches could be quite meaningful to top-line growth. On top of launches, Rocket Lab has built and bought capabilities in the space systems sector, which encompasses items that you put onto payloads in space such as satellites and solar arrays. It just acquired a company called Geost to help further its vertical integration into the defense satellite sector, a highly important capability to have today. In fact, over 70% of Rocket Lab's Q1 revenue came from the space systems segment, making it a much larger market opportunity than just rocket launches. A vertically integrated space company is an ambitious goal, and Rocket Lab is aiming to build it from launch to space gear to eventually software services, according to management. It has a nice narrative, but it is not guaranteed to work. For one, the Neutron rocket has never even performed a test launch. As investors have recently seen with SpaceX and its Starship tests, mishaps in testing can lead to disastrous (and expensive) results. Rocket Lab is currently unprofitable, burning $177 million in annual free cash flow as it builds out the Neutron and other space system segments. With just over $500 million in cash and equivalents, the company is only a few years of cash burn and failed tests of the Neutron rocket from running into a liquidity concern. These are unproven markets, and while Rocket Lab is innovating in a field that could potentially be worth tens of billions of dollars someday, its business plan comes with a lot of risks. After soaring 600% in the last 12 months, Rocket Lab now trades at a market cap of $15 billion. That brings its trailing price-to-sales ratio (P/S) to a sky-high level of 36. For reference, the S&P 500 trades at an average P/S ratio of 3, or about 10% the level of Rocket Lab. Yes, Rocket Lab has a higher growth potential than the average stock, and could easily be generating billions of dollars in revenue in the future. It is not guaranteed to do so, though. Even if Rocket Lab reaches $3 billion in sales -- close to 10x today's level -- it is unclear how much of that would translate to bottom-line profits due to its low gross margins below 30%. If it achieves a bottom-line profit margin of 10%, that would equate to $300 million in annual earnings, or a price-to-earnings ratio (P/E) of over 50 compared to its current market cap. And these earnings will not materialize for many years, if they end up doing so at all. However you slice it, Rocket Lab looks like an overvalued stock that has gotten ahead of itself in the last year or so. Avoid buying Rocket Lab for your portfolio. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $409,114!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,173!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $713,547!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 23, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy. Should You Buy Rocket Lab While It's Below $40? was originally published by The Motley Fool
